# Determination of Molecular Status, the Efficacy and Safety of Fluorodeoxyglucose in PET-CT Imaging

> **NCT04943211** · PHASE3 · RECRUITING · sponsor: **Anna Raciborska** · enrollment: 150 (estimated)

## Conditions studied

- Histiocytosis

## Interventions

- **DRUG:** fluorodeoxyglucose (18F-FDG)

## Key facts

- **NCT ID:** NCT04943211
- **Lead sponsor:** Anna Raciborska
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2021-04-01
- **Primary completion:** 2027-06-30
- **Final completion:** 2027-06-30
- **Target enrollment:** 150 (ESTIMATED)
- **Last updated:** 2026-03-25

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04943211

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04943211, "Determination of Molecular Status, the Efficacy and Safety of Fluorodeoxyglucose in PET-CT Imaging". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04943211. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*